Publication Name	World Journal of Clinical Oncology
Manuscript ID	8645
Country	United States

Received	2013-12-31 15:57
Peer-Review Started	2013-12-31 21:47
To Make the First Decision	2014-01-23 17:09
Return for Revision	2014-02-09 21:08
Revised	2014-03-05 07:08
Second Decision	2014-04-17 14:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-17 15:23
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-07 14:44
Publish the Manuscript Online	2014-05-12 18:06

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Targeted immunotherapy for non-small cell lung cancer
Manuscript Source	Invited Manuscript
All Author List	Monali Vasekar, Xin Liu, Hong Zheng and Chandra P Belani
Funding Agency and Grant Number
Corresponding Author	Chandra P Belani, MD, Penn State Hershey Cancer Institute, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, United States. cbelani@hmc.psu.edu
Key Words	Immunotherapy; Non-small cell lung cancer; Programmed death-1; Programmed death ligands 1; Cytotoxic T-Lymphocyte Antigen-4
Core Tip	Lung cancer is the leading cause of cancer-death worldwide. Majority of these patients have non-small cell lung cancer (NSCLC). Traditional chemotherapy is limited by its high toxicity. Emerging data have demonstrated promising outcome of immunotherapy in NSCLC. This review delineated the rationale and potential targets of cancer immunotherapy, with a summary of immunotherapeutic agents for treatment of NSCLC. Protein/peptide-based and cell-based vaccines, as well as immune checkpoint targeted agents such as Ipilimumab and PD-1 pathway inhibitors were discussed. In addition, we reviewed ongoing immunotherapy-based studies including several major phase II/III clinical trials, results of which will be available soon for incorporation into clinical practice.
Publish Date	2014-05-12 18:06
Citation	Vasekar M, Liu X, Zheng H, Belani CP. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014; 5(2): 39-47
URL	http://www.wjgnet.com/2218-4333/full/v5/i2/39.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i2.39

Full Article (PDF)	WJCO-5-39.pdf
Full Article (Word)	WJCO-5-39.doc
Manuscript File	8645-Review.doc
Answering Reviewers	8645-Answering reviewers.pdf
Copyright License Agreement	8645-Copyright assignment.pdf
Peer-review Report	8645-Peer review(s).pdf
Scientific Editor Work List	8645-Scientific editor work list.doc